Richard Nowak, MD, MS
Associate Professor of NeurologyCards
About
Research
Overview
https://medicine.yale.edu/neurology/divisions/neuromuscular/nmresearch.aspx
Medical Research Interests
Amyotrophic Lateral Sclerosis; Charcot-Marie-Tooth Disease; Guillain-Barre Syndrome; Myasthenia Gravis; Neurology; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Publications
2024
Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination
Garbey M, Lesport Q, Girma H, Öztosun G, Abu-Rub M, Guidon A, Juel V, Nowak R, Soliven B, Aban I, Kaminski H. Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination. Frontiers In Neurology 2024, 15: 1474884. PMID: 39697445, PMCID: PMC11652356, DOI: 10.3389/fneur.2024.1474884.Peer-Reviewed Original ResearchNatural language processingMyasthenia gravisArtificial intelligenceArtificial intelligence methodsSeries of algorithmsComputer visionSignal processing methodsExamination of patientsConventional clinical settingsLanguage processingIntelligence methodsNon-physician healthcare providersVideoControl subjectsClinical trialsPatientsRespiratory metricsMyastheniaBreath countClinical settingAlgorithmBody motionVideos of patientsTelemedicine evaluationIntelligenceUS Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization
Nowak R, Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Howard J. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes 2024, 11: 593-601. PMID: 39470958, PMCID: PMC11589080, DOI: 10.1007/s40801-024-00457-8.Peer-Reviewed Original ResearchHealthcare resource utilizationAssociated healthcare resource utilizationRescue therapy useEculizumab treatmentMyasthenia gravisMG exacerbationEculizumab initiationTherapy useMethodsA retrospective chart reviewTerminal complement inhibitor eculizumabRetrospective chart review analysisRates of healthcare resource utilizationComplement inhibitor eculizumabGeneralized myasthenia gravisRetrospective chart reviewChart review analysisTreatment of patientsUS adultsEculizumab therapyAcute clinical eventsMG crisisRescue therapyChart reviewEculizumabTherapy administrationFluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy
Baxter L, Hopkins S, O'Connor K, Pham M, Nowak R, Monson N, Blackburn K, Hibbs R, Vernino S, Noviello C. Fluorescence-detection size-exclusion chromatography specifically detects autoantibodies targeting the ganglionic acetylcholine receptor in patients with autoimmune autonomic ganglionopathy. Journal Of Neuroimmunology 2024, 396: 578454. PMID: 39277987, DOI: 10.1016/j.jneuroim.2024.578454.Peer-Reviewed Original ResearchAutoimmune autonomic ganglionopathyGanglionic acetylcholine receptorAutonomic ganglionopathyRadioimmunoprecipitation assayFluorescence-detection size-exclusion chromatographyAcetylcholine receptorsAutoantibody detectionClinical symptomsDetect autoantibodiesAutoimmune diseasesHealthy controlsPatient seraSize-exclusion-chromatographyAutoantibodiesGAChRGanglionopathySize exclusion chromatographyPatientsReceptorsUnited States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use
Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Nowak R, Howard J. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. Journal Of Neurology 2024, 271: 6114-6126. PMID: 39052039, PMCID: PMC11377470, DOI: 10.1007/s00415-024-12569-w.Peer-Reviewed Original ResearchMinimal symptom expression’Minimal manifestation statusGeneralized myasthenia gravisEculizumab initiationEculizumab treatmentTotal scoreMG-ADLPrednisone dosageMyasthenia gravisMethodsA retrospective chart reviewComplement C5 inhibitor eculizumabSteroid-sparing effectAssociated with sustained improvementOpen-label extensionEffectiveness of eculizumabImmunosuppressive therapy useConcomitant medication useRetrospective chart reviewNonsteroidal immunosuppressive therapyMyasthenia Gravis-ActivitiesTreatment-refractoryC5 inhibitor eculizumabDiscontinue prednisoneImmunosuppressive therapySymptom expressionPhenotypes of B Cells Producing Autoantibodies in MOGAD Patients (N1.002)
Filipek B, Yandamuri S, Obaid A, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O’Connor K. Phenotypes of B Cells Producing Autoantibodies in MOGAD Patients (N1.002). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000208259.Peer-Reviewed Original ResearchProteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003)
Roy B, Habiabadi F, O’Connor K, Nowak R, Kaminski H. Proteomic Analysis Reveals a Distinct Immunological Signature for Late-onset Myasthenia Gravis (S15.003). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205944.Peer-Reviewed Original ResearchEffectiveness of Eculizumab Treatment by Time from Diagnosis in Patients with Generalized Myasthenia Gravis: A Retrospective Electronic Medical Record Analysis (S15.006)
Muppidi S, Lee J, Habib A, Howard J, Klink A, Kielhorn A, Sabatella G, Nowak R. Effectiveness of Eculizumab Treatment by Time from Diagnosis in Patients with Generalized Myasthenia Gravis: A Retrospective Electronic Medical Record Analysis (S15.006). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205156.Peer-Reviewed Original ResearchTrial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004)
Roy B, Nowak R. Trial Design and Impact on Study Outcome: Post-hoc Analysis of the BeatMG Study Based on RINOMAX Trial Criteria (P4-11.004). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205956.Peer-Reviewed Original ResearchA Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases.
Yandamuri S, Filipek B, Lele N, Cohen I, Bennett J, Nowak R, Sotirchos E, Longbrake E, Mace E, O'Connor K. A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. The Journal Of Immunology 2024, 212: 785-800. PMID: 38251887, PMCID: PMC10932911, DOI: 10.4049/jimmunol.2300015.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderAb-dependent cellular cytotoxicityNK cellsMyasthenia gravisMG patientsInduced Ab-dependent cellular cytotoxicityNK cell-mediated effector functionsPeripheral blood immune cell populationsCell-mediated effector functionsNeuromyelitis optica spectrum disorder patientsBlood immune cell populationsAb-dependent cellular cytotoxicity activityNK marker CD56NK cell markersHLA-DR expressionNK cell subsetsExpression of perforinImmune cell populationsAutoimmune myasthenia gravisElevated disease burdenHLA-DRCell subsetsCellular cytotoxicityChemokine receptorsMultiparameter immunophenotyping
2023
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
Antozzi C, Guptill J, Bril V, Gamez J, Meuth S, Nowak R, Quan D, Sevilla T, Jouvin M, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S, Group F. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis. Neurology 2023, 102: e207937. PMID: 38165333, PMCID: PMC10962909, DOI: 10.1212/wnl.0000000000207937.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsGeneralized myasthenia gravisSignificant dose responseAdverse eventsMG-ADLDay 57Myasthenia gravisDose responseMyasthenia Gravis ActivitiesPrimary safety endpointPrimary efficacy endpointSerious adverse eventsPhase 2 studyReceptor monoclonal antibodyDaily living (IADL) total scoreClinical trial registrationMG-ADL scoreDose-dependent reductionEudraCT numberQ2W groupEfficacy endpointPlacebo groupSafety endpointCare therapyReceptor autoantibodies
Clinical Trials
Current Trials
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
HIC ID2000031341RolePrincipal InvestigatorPrimary Completion Date02/21/2024Recruiting ParticipantsGenderBothAge18+ yearsMyasthenia Gravis Inebilizumab Trial (MINT)
HIC ID2000029503RolePrincipal InvestigatorPrimary Completion Date06/30/2023Recruiting ParticipantsGenderBothAge18+ yearsRegistry of Patients With Generalized Myasthenia Gravis Who Have Ever Been Treated With C5 Inhibition Therapies
HIC ID2000026785REGRolePrincipal InvestigatorPrimary Completion Date12/31/2021Recruiting ParticipantsExploring Outcomes and Characteristics of Myasthenia Gravis 2 (EXPLORE-MG2)
HIC ID2000026920REGRolePrincipal InvestigatorPrimary Completion Date12/31/2022Recruiting ParticipantsOpen-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)
HIC ID2000026786RolePrincipal InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsGenderBothAge40 years - 80 years
Clinical Care
Overview
Richard Nowak, MD, MS, is the director of the Yale Myasthenia Gravis Clinic, where he treats patients with the chronic, autoimmune condition that causes muscles to tire and weaken easily. He provides personalized treatment strategies for patients suffering from myasthenia gravis and other autoimmune neuromuscular conditions.
In addition, Dr. Nowak works with the Yale Medicine Neuromuscular Medicine Program, which is supported by the Muscular Dystrophy Association (MDA), and is a designated MDA-ALS clinic. The program provides comprehensive diagnostic evaluation, consultation and management for a range of neuromuscular disorders.
An associate professor of neurology at Yale School of Medicine, Dr. Nowak is also a busy researcher who directs the Program in Clinical and Translational Neuromuscular Research at Yale, where his goal is to improve the understanding of autoimmune neuromuscular disorders, identify new drug targets and explore new therapies. In 2013, he was awarded a $4.8 million grant to conduct the first clinical trial for myasthenia gravis sponsored by the National Institutes of Health.
Clinical Specialties
Neuromuscular Medicine
Fact Sheets
Stiff Person Syndrome (SPS)
Learn More on Yale MedicineMyasthenia Gravis
Learn More on Yale MedicineAmyloidosis
Learn More on Yale MedicineGuillain-Barré Syndrome
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
- November 17, 2023Source: Yale Medicine
Myasthenia Gravis: New Drugs and a Road to Individualized Treatment
- November 06, 2023Source: Medpage Today
What's on the Horizon for Myasthenia Gravis – Cell-based therapies, broader B-cell targeting, and immune tolerance are all in the works
- November 03, 2023Source: Medpage Today
A Changing Treatment Landscape in Myasthenia Gravis – A spate of new approvals set off a "revolution" in management
- April 12, 2023
Nowak Receives Impact Award
Get In Touch
Contacts
Administrative Support
Locations
Yale School of Medicine, Department of Neurology
Academic Office
Hunter Building
15 York Street, Ste 9th floor
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.